Senores Pharmaceuticals Ltd.

•

senorespharma.comBSE: 544319NSE: SENORES

Market Cap₹ 6,597 Cr.

Current Price

High / Low₹ 1,599 / 662

Stock P/E354.9

Book Value₹ 163

Price to Book4.66

Dividend Yield0.00 %

ROCE4.2 %

ROE2.8 %

Face Value₹ 10

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence

50%

View full sector analysis →

PROS

Company is almost debt free
Working capital cycle has improved - days down from 3513 to 640
Institutional investors have been accumulating - FII+DII up 3.2pp

CONS

Company is loss-making at the operating / net level
A large part of profit comes from other income (241.6% of PBT)
Operating cash flow has been negative in recent years
Recent results are weak - TTM profit is down 26.8% versus prior year
Company has a low return on capital employed of 3.0%
Company has a low return on equity of 1.5% over last 3 years

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs

Part ofNIFTY 50 NIFTY 500 NIFTY LARGEMIDCAP 250 NIFTY 100 NIFTY 200

S.No.	Name
1.	SUNPHARMA	1904.00	37.77	456833.38	0.84	2901.23	26.53	15299.88	10.98	19.11	28.81
2.	DIVISLAB	9245.00	83.91	245425.70	0.32	902.00	65.50	3080.00	27.80	21.51	40.75
3.	TORNTPHARM	4924.70	85.89	187319.76	0.77	566.00	3.28	4921.00	57.32	19.27	33.81
4.	ZYDUSLIFE	1135.00	25.09	113216.68	0.09	990.20	-34.90	8017.00	23.97	21.39	24.54
5.	CIPLA	1389.00	33.29	112211.54	0.94	785.55	-39.18	7119.28	4.13	16.00	16.73
6.	LAURUSLABS	1872.15	92.52	101154.55	0.11	362.07	123.94	2026.31	29.10	18.20	31.50
7.	LUPIN	2135.00	17.66	97626.26	0.84	1416.98	16.01	8276.89	34.28	28.86	29.59
8.	MANKIND	2345.00	47.42	96859.07	0.04	574.09	29.12	4030.59	12.89	13.24	26.30
9.	DRREDDY	1155.00	29.92	96405.53	0.69	435.60	-69.10	8099.80	-5.21	13.75	10.63
10.	AUROPHARMA	1627.00	25.22	93613.98	0.25	1032.03	25.22	9150.35	17.44	12.76	20.54
11.	GLENMARK	2458.80	38.60	69393.40	0.10	482.83	927.88	4018.48	31.35	20.35	20.03
12.	SENORES	1432.45	52.20	6596.95	0.00	30.45	43.77	180.21	38.30	15.66	29.83

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	9	11	7	10	10	12	15	21	17	37	27
	9	9	8	11	12	15	21	34	30	40	35
Operating Profit	-1	2	-1	-1	-2	-3	-5	-13	-13	-3	-8
OPM %	-5.95%	17.72%	-10.43%	-13.91%	-25.23%	-23.02%	-35.44%	-61.57%	-79.61%	-9.45%	-30.23%
	2	5	2	3	7	9	8	11	10	22	10
Interest	1	1	1	1	3	2	2	2	2	2	2
Depreciation	0	1	1	1	1	1	2	4	4	4	4
Profit before Tax	0	6	0	1	1	3	4	8	4	13	1
Tax %	59.18%	158.83%	11.43%	44.44%	18.94%	30.34%	24.79%	16.06%	24.72%	33.18%	25.90%
Net Profit	0	-3	0	0	1	2	3	6	3	8	1
	0.08	-1.05	0.09	0.09	0.32	0.39	0.59	1.40	1.98	1.84	0.22

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	14	12	34	39	106	101
	12	14	34	46	125	139
Operating Profit	1	-2	-0	-7	-19	-38
OPM %	8.54%	-14.38%	-0.21%	-18.89%	-17.61%	-37.21%
	1	7	7	22	66	53
Interest	1	2	3	7	7	7
Depreciation	1	1	2	3	13	15
Profit before Tax	1	2	2	5	27	25
Tax %	18.24%	38.23%	60.10%	27.79%	26.26%	26.41%
Net Profit	1	1	1	4	20	19
EPS	1.24	0.95	0.27	0.80	4.40	—
Dividend Payout %	0.00%	0.00%	0.00%	0.00%	0.00%	—

COMPOUNDED SALES GROWTH

10 Years:: —
5 Years:: —
3 Years:: 105%

COMPOUNDED PROFIT GROWTH

10 Years:: —
5 Years:: —
3 Years:: 157%

STOCK PRICE CAGR

10 Years:: —
5 Years:: —
3 Years:: —
1 Year:: 103%

RETURN ON EQUITY

10 Years:: —
5 Years:: 2%
3 Years:: 1%
Last Year:: 3%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	9	10	31	46	46
	25	29	138	662	704
	15	56	99	93	82
Trade Payables	6	4	12	13	31
	0	12	7	20	24
Total Liabilities	55	112	286	834	886
	2	8	24	55	98
Capital Work in Progress	0	8	15	34	9
	12	8	82	104	154
	3	3	5	9	10
	0	0	22	26	76
Cash & Bank	1	0	10	360	146
	37	84	128	247	393
Total Assets	55	112	286	834	886

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-24	-43	-19	-20	-27
Cash from Investing	-10	-5	-57	-436	-19
Cash from Financing	34	47	87	533	-3
	-0	-2	10	76	-49

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
PER SHARE
EPS (₹)	0.78	1.22	0.27	0.80	4.40
Book Value (₹)	38.54	39.66	55.10	153.74	162.78
Dividend per Share (₹)	0.00	0.00	0.00	0.00	0.00
Cash EPS (₹)	1.59	2.17	0.93	1.47	7.27
PROFITABILITY
Operating Margin %	15.47%	40.48%	-0.21%	-18.89%	-17.61%
Net Margin %	5.03%	9.68%	2.38%	9.57%	19.09%
ROE %	2.02%	3.30%	0.78%	0.84%	2.78%
ROCE %	2.90%	5.54%	2.63%	2.19%	4.24%
	1.25%	1.44%	0.41%	0.66%	2.35%
EFFICIENCY
Debtor Days	226	355	202	226	176
Inventory Days	80	90	41	62	32
Payable Days	269	325	151	253	149
	37	120	92	35	59
FINANCIAL HEALTH
Debt to Equity (x)	0.42x	1.55x	0.55x	0.13x	0.10x
Interest Coverage (x)	2.50x	1.91x	1.75x	1.78x	4.93x
	1.59x	0.59x	0.44x	9.99x	3.67x
GROWTH
Revenue Growth %	0.00%	-8.58%	174.67%	13.32%	175.27%
Operating Profit Growth %	0.00%	139.22%	35.28%	116.96%	224.07%
Net Profit Growth %	0.00%	75.86%	-32.44%	355.56%	448.78%
	0.00%	0.00%	-78.27%	201.81%	448.78%
VALUATION
P/E (x)	0.00x	0.00x	0.00x	714.78x	172.35x
P/B (x)	0.00x	0.00x	0.00x	3.73x	4.66x
Dividend Yield %	0.00%	0.00%	0.00%	0.00%	0.00%
	0.00x	0.00x	16.64x	161.23x	71.65x

Shareholding Pattern

Numbers in percentages

	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	45.76	45.76	45.77	45.78	45.80	45.80	45.82	45.82
	5.52	4.24	4.17	3.66	4.28	3.35	3.64	6.62
	16.61	11.49	9.66	9.51	8.62	9.32	9.62	9.77
Government	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	32.11	38.48	40.40	41.04	41.31	41.54	40.93	37.79

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-04

Copy of Newspaper Publication

2026-09-04 - Senores Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication with respect to the 9th Annual General Meeting of the Company.

2026-09-03

Shareholders meeting

2026-09-03 - Senores Pharmaceuticals Limited has informed the Exchange regarding Notice of 9th Annual General Meeting to be held on September 25, 2026

2026-08-27

Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-27 - Senores Pharmaceuticals Limited has informed the Exchange about Schedule of meet

2026-08-27

Copy of Newspaper Publication

2026-08-27 - Senores Pharmaceuticals Limited has informed the Exchange regarding copy of newspaper publication for pre dispatch of Annual Report for the forthcoming Annual General Meeting of the Company

2026-08-26

Appointment

2026-08-26 - Senores Pharmaceuticals Limited has informed the Exchange regarding Appointment of Mr Viranchi Arvindbhai Shah as Non- Executive Independent Director of the company w.e.f. August 26, 2026.

2026-08-26

General Updates

2026-08-26 - Approval of Senores Pharmaceuticals Employee Stock Option Scheme 2026 ( ESOS 2026 / SCHEME )

2026-08-26

General Updates

2026-08-26 - Proposed incorporation of a Wholly Owned Subsidiary (WOS) in Mexico

2026-08-26

General Updates

2026-08-26 - Proposed incorporation of a Subsidiary Company in Canada

2026-08-26

Outcome of Board Meeting

2026-08-26 - Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 26, 2026.